Review|Volume 12, Issue 24|pp 26263—26278

Immunometabolism at the cornerstone of inflammaging, immunosenescence, and autoimmunity in COVID-19

Loukman Omarjee^1,², Frédérique Perrot³, Olivier Meilhac⁴, Guillaume Mahe¹, Guilhem Bousquet^5,⁶, Anne Janin^6,⁷

¹Vascular Medicine Department, CHU Rennes, French National Health and Medical Research (Inserm), Clinical Investigation Center (CIC) 1414, University of Rennes 1, Rennes F-35033, France
²NuMeCan Institute, Exogenous and Endogenous Stress and Pathological Responses in Hepato-Gastrointestinal Diseases (EXPRES) Team, French National Health and Medical Research (Inserm) U1241, University of Rennes 1, Rennes F-35033, France
³Cellular and Molecular Biology Consultant, Rennes F-35033, France
⁴University of Reunion Island, INSERM, UMR 1188 Reunion, Indian Ocean Diabetic Atherothrombosis Therapies (DéTROI), CHU de La Réunion, Saint-Denis de La Réunion F-97400, France
⁵AP-HP Hôpital Avicenne, Oncologie Médicale, Bobigny F-93000, France
⁶Sorbonne University Paris Nord, INSERM, U942, Cardiovascular Markers in Stressed Conditions, MASCOT, Bobigny F-93000, France
⁷Department of Pathology, Paris Diderot University, Sorbonne Paris Cité, Paris F-75010, France

Received: October 29, 2020Accepted: December 10, 2020Published: December 27, 2020

https://doi.org/10.18632/aging.202422

Copyright: © 2020 Omarjee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Inflammaging constitutes the common factor for comorbidities predisposing to severe COVID-19. Inflammaging leads to T-cell senescence, and immunosenescence is linked to autoimmune manifestations in COVID-19. As in SLE, metabolic dysregulation occurs in T-cells. Targeting this T-cell dysfunction opens the field for new therapeutic strategies to prevent severe COVID-19. Immunometabolism-mediated approaches such as rapamycin, metformin and dimethyl fumarate, may optimize COVID-19 treatment of the elderly and patients at risk for severe disease.